Determining medical decision-making capacity in brain tumor patients:why and how?
| Autor: | Simon Kerrigan, Johan A F Koekkoek, Tobias Walbert, Simone Veronese, Stefan Oberndorfer, Andrea Pace, Roger Henriksson, H. Roeline W. Pasman, Jane Fleming, Helen Bulbeck, Christine Marosi, Robin Grant, Alasdair G Rooney, Michael Weller, Wolfgang Wick, Martin J B Taphoorn, Kathy Oliver, Roberta Rudà, Martin J. van den Bent, Heidrun Golla, Linda Dirven, Emilie Le Rhun, Ingela Oberg |
|---|---|
| Přispěvatelé: | INSERM, Université de Lille, Leiden University Medical Center [LUMC], Erasmus University Medical Center [Rotterdam] [Erasmus MC], University Hospital of Cologne [Cologne], Umeå University, Medizinische Universität Wien = Medical University of Vienna, Cambridge University Hospitals - NHS [CUH], St. Pölten University of Applied Sciences, Amsterdam University Medical Centers [Amsterdam UMC], Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192, University of Edinburgh, Università degli studi di Torino = University of Turin [UNITO], Henry Ford Health System, University hospital of Zurich [Zurich], Heidelberg University Hospital [Heidelberg], Neurology, Leiden University Medical Center (LUMC), Universiteit Leiden, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Cambridge University Hospitals - NHS (CUH), University of Cambridge [UK] (CAM), Amsterdam University Medical Centers (Amsterdam UMC), Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 (PRISM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Università degli studi di Torino = University of Turin (UNITO) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Palliative care [SDV]Life Sciences [q-bio] Psychological intervention Brain tumor Reviews Medicine (miscellaneous) Best interests 03 medical and health sciences 0302 clinical medicine neurodegenerative disease Informed consent brain metastases glioma Medicine Intensive care medicine Cognitive impairment business.industry Consent to treatment capacity Medical decision making medicine.disease 030220 oncology & carcinogenesis consent business 030217 neurology & neurosurgery |
| Zdroj: | Neuro-Oncology Practice, 7(6), 599-612. Oxford University Press Neuro Oncology Practice, 7(6), 599-612. OXFORD UNIV PRESS Neuro-Oncology Practice Neuro-Oncology Practice, 2020, Neuro-oncology practice, 7 (6), pp.599-612. ⟨10.1093/nop/npaa040⟩ Neurooncol Pract Pace, A, Koekkoek, J A F, Van Den Bent, M J, Bulbeck, H J, Fleming, J, Grant, R, Golla, H, Henriksson, R, Kerrigan, S, Marosi, C, Oberg, I, Oberndorfer, S, Oliver, K, Pasman, H R W, Le Rhun, E, Rooney, A G, Rudà, R, Veronese, S, Walbert, T, Weller, M, Wick, W, Taphoorn, M J B & Dirven, L 2020, ' Determining medical decision-making capacity in brain tumor patients: why and how? ', Neuro-Oncology Practice . https://doi.org/10.1093/nop/npaa040 |
| ISSN: | 2054-2577 2054-2585 |
| DOI: | 10.1093/nop/npaa040⟩ |
| Popis: | Background Brain tumor patients are at high risk of impaired medical decision-making capacity (MDC), which can be ethically challenging because it limits their ability to give informed consent to medical treatments or participation in research. The European Association of Neuro-Oncology Palliative Care Multidisciplinary Task Force performed a systematic review to identify relevant evidence with respect to MDC that could be used to give recommendations on how to cope with reduced MDC in brain tumor patients. Methods A literature search in several electronic databases was conducted up to September 2019, including studies with brain tumor and other neurological patients. Information related to the following topics was extracted: tools to measure MDC, consent to treatment or research, predictive patient- and treatment-related factors, surrogate decision making, and interventions to improve MDC. Results A total of 138 articles were deemed eligible. Several structured capacity-assessment instruments are available to aid clinical decision making. These instruments revealed a high incidence of impaired MDC both in brain tumors and other neurological diseases for treatment- and research-related decisions. Incapacity appeared to be mostly determined by the level of cognitive impairment. Surrogate decision making should be considered in case a patient lacks capacity, ensuring that the patient’s “best interests” and wishes are guaranteed. Several methods are available that may help to enhance patients’ consent capacity. Conclusions Clinical recommendations on how to detect and manage reduced MDC in brain tumor patients were formulated, reflecting among others the timing of MDC assessments, methods to enhance patients’ consent capacity, and alternative procedures, including surrogate consent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|